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Abstract
Although antiretroviral treatment decreases HIV-AIDS morbidity/mortality, long-term side effects may include the onset of
insulin resistance and cardiovascular diseases. However, the underlying molecular mechanisms responsible for highly active
antiretroviral therapy (HAART)-induced cardio-metabolic effects are poorly understood. In light of this, we hypothesized that
HIV protease inhibitor (PI) treatment (Lopinavir/Ritonavir) elevates myocardial oxidative stress and concomitantly inhibits
the ubiquitin proteasome system (UPS), thereby attenuating cardiac function. Lopinavir/Ritonavir was dissolved in 1%
ethanol (vehicle) and injected into mini-osmotic pumps that were surgically implanted into Wistar rats for 8 weeks vs.
vehicle and sham controls. We subsequently evaluated metabolic parameters, gene/protein markers and heart function (ex
vivo Langendorff perfusions). PI-treated rats exhibited increased serum LDL-cholesterol, higher tissue triglycerides (heart,
liver), but no evidence of insulin resistance. In parallel, there was upregulation of hepatic gene expression, i.e. acetyl-CoA
carboxylase b and 3-hydroxy-3-methylglutaryl-CoA-reductase, key regulators of fatty acid oxidation and cholesterol
synthesis, respectively. PI-treated hearts displayed impaired cardiac contractile function together with attenuated UPS
activity. However, there was no significant remodeling of hearts exposed to PIs, i.e. lack of ultrastructural changes, fibrosis,
cardiac hypertrophic response, and oxidative stress. Western blot analysis of PI-treated hearts revealed that perturbed
calcium handling may contribute to the PI-mediated contractile dysfunction. Here chronic PI administration led to elevated
myocardial calcineurin, nuclear factor of activated T-cells 3 (NFAT3), connexin 43, and phosphorylated phospholamban,
together with decreased calmodulin expression levels. This study demonstrates that early changes triggered by PI treatment
include increased serum LDL-cholesterol levels together with attenuated cardiac function. Furthermore, PI exposure inhibits
the myocardial UPS and leads to elevated calcineurin and connexin 43 expression that may be associated with the future
onset of cardiac contractile dysfunction.
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Introduction
The human immunodeficiency virus (HIV) has infected over
40 million individuals over the last decade, with more than
5 million residing in sub-Saharan Africa [1,2]. Although highly
active antiretroviral therapy (HAART) enhances life expectancy
and quality of infected individuals [3,4], there is increased
emphasis on HAART-mediated metabolic derangements [5] and
its potential risk for cardiovascular diseases (CVD) in the long-
term.
Protease inhibitors (PIs) form an integral part of HAART and
side-effects include development of dyslipidemia, i.e. greater
production of plasma triglycerides and lipids together with an
adverse cholesterol profile [6–8]. Together such derangements
elicit inflammation, stress the myocardium (9), and may potentially
predict the onset of insulin resistance (IR) [10,11] and cardiac
dysfunction (11). PIs are also linked to increased risk for
myocardial infarction [13] and cardiovascular abnormalities
[14,15], with many changes resembling coronary artery disease
[16]. It is unclear whether metabolic side effects of PIs are
independently and/or causally linked with cardiovascular pertur-
bations. Moreover, the effects of PIs per se on the heart in this
context are also poorly understood. Therefore, an emerging focus
is to identify key metabolic and transcriptional pathways that may
mediate PI-induced cardio-metabolic pathophysiology. For exam-
ple, we recently found that rats exposed to 8 weeks of PI treatment
displayed cardiac dysfunction [17]. Moreover, PI-treated HIV-
infected individuals exhibit elevated reactive oxygen species (ROS)
production [18–20] that may trigger the activation of detrimental
signaling and cell death pathways [21].
HIV-PIs may also exert unfavorable effects at the gene
transcriptional level, e.g. activating sterol regulatory element
binding protein (SREBP) [22], a key lipid transcriptional
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modulator expressed in major metabolic tissues [23]. Upon
activation, SREBP binds to sterol-regulatory-element (SRE)-
containing promoter sequences in lipogenic and cholesterogenic
genes (e.g. 3-hydroxy-3-methyl-glutaryl-CoA reductase [hmgcr])
that ultimately results in the production of cholesterol (high and
low density lipoproteins) and sterol components [24]. The
ubiquitin-proteasome system (UPS) – responsible for removal of
misfolded or damaged proteins – is also implicated in the onset of
such metabolic side effects. For example, the PI Ritonavir
attenuates chymotrypsin- and trypsin-like activities of the 20S
UPS subunit in hepatocytes [25]. As a result, degradation of
apolipoprotein B (major determinant of plasma lipid levels) was
diminished thus providing a potential mechanism for PI-induced
hyperlipidemia [26]. Furthermore, SREBPs are ubiquitinated and
degraded by the UPS [27,28] raising the possibility that an
inhibition of this system may also contribute to development of
dyslipidemia in HIV-infected individuals treated with PIs.
Together this may establish a pro-atherogenic profile and increase
the risk for the onset of CVD.
Despite such progress, the underlying molecular mechanisms
responsible for HAART-induced cardio-metabolic side effects are
poorly understood, and little is known about the earliest events
driving this process. Whether these molecular alterations occur as
a direct result of PI treatment or through the activation of
additional pathways throughout the body at a later stage remain
elusive. For the current study, we therefore hypothesized that PI
treatment enhances myocardial oxidative stress and concomitantly
inhibits the UPS, having a knock-on effect on important
downstream regulators such as gap junctions and ion channels
essential in cardiac physiology. We also evaluated several non-
oxidative glucose metabolic circuits i.e. the polyol pathway,
hexosamine biosynthetic pathway (HBP), advanced glycation
end products (AGE), and PKC activation since previous work
found its activation can elicit the onset of cardio-metabolic
complications [29]. Since our previous ex vivo rat heart study [17]
implicated altered calcium homeostasis in PI-mediated cardiac
dysfunction, we further investigated calcium signaling and
mitochondrial energetic regulators in an established rat model of
chronic PI drug delivery. These data may explain and suggest an
association between molecular changes and depressed cardiac
contractile function.
Materials and Methods
Animal model. Lopinavir/Ritonavir (KaletraTM, Abbott
Laboratories, Abbot Park IL) was crushed and dissolved in a 1%
ethanol (vehicle) solution at human steady-state plasma concen-
tration (7.162.9 mg/mL), sterile filtered and injected into a mini-
osmotic pump (Alzet, Cupertino CA). Male Wistar rats (180–
220 g) received either: mock surgery (sham), vehicle-, or PI-
containing pump for a total of 8 weeks (n = 8 per group) as
previously described [17]. Food consumption was measured via
weekly weighing of the food (in cages) and expressed as average
food consumed per rat. All animals were treated in accordance
with the Guide for the Care and Use of Laboratory Animals of the
National Academy of Sciences (NIH publication No. 85–23,
revised 1996) and performed with the approval of the Animal
Ethics Committee of Stellenbosch University (South Africa).
Baseline heart function assessment. After 8 weeks rats
were euthanized with pentobarbitone-sodium (10 mg/kg, i.p.)
and hearts rapidly excised, weighed and placed into ice-cold
Krebs-Henseleit (KH) buffer before cannulation on a Langen-
dorff perfusion rig as previously described [17]. The cannulation
and perfusion occurred within ,1.5 min of excision for all
hearts. Additional parameters to the ones we have previously
published include 6dP/dt and heart rate during 60 min of
perfusion.
Histologic and metabolic measurements. After 8 weeks,
harvested tissues (heart, liver, adipose, pancreas and skeletal
muscle) were fixed, processed and embedded in paraffin wax
whereafter sections were stained with a) hematoxylin and eosin (H
& E) for general morphologic evaluation and b) Sirius red for
detection of collagen deposits (fibrosis).
In an identical cohort of animals, we evaluated both serum and
tissue metabolite levels following PI treatment. After 8 weeks (4–
7 days before termination of treatment period) rats underwent a
12–18 h overnight fast whereafter blood was collected from the
jugular vein under anesthesia (isofluorane in oxygen, 5% for
induction and 3% for maintenance). Serum was isolated from the
collected blood and analyzed for: total and LDL cholesterol, free
fatty acids (FFA) and triglyceride (TG) levels (NHLS, Tygerberg
Hospital, South Africa). We also evaluated the homeostatic model
of assessment for insulin resistance (HOMA-IR) – here serum
insulin and glucose levels were also determined (PathCare
Laboratory, Stellenbosch, South Africa). The HOMA-IR was
calculated as follows: (glucose [mg/dL] x fasting insulin [mU/
mL]/2.43) and the equation used in accordance with the
guidelines for HOMA-IR assessment in rodents [30].
Isolated heart and liver tissues were also assessed for: total
cholesterol, HDL, LDL/VLDL cholesterol (Abcam, Cambridge
MA) and TG content (BioVision, Milpitas CA) according to the
manufacturer’s instructions.
Real-time qPCR analysis for gene expression. Total
RNA was isolated from homogenized liver and heart tissues
(n = 8) using the RNeasyH Mini Kit (Qiagen, Germantown, MD)
according to the manufacturer’s protocols as previously described
[31,32]. First strand cDNA was made using the iScriptTM cDNA
synthesis kit (BioRad, Hercules CA) using 200 & 250 ng of RNA
from liver, and heart tissue, respectively, and included the Solaris
synthetic RNA Spike Control (Thermo Scientific, Waltham MA)
to test for reverse transcription and PCR inhibition. Samples that
did not show significant inhibition (DCq ,3 compared to synthetic
target alone, 69 of 72 samples) were diluted 20-fold in water and
used for gene expression analysis. A total of three samples
exhibited inhibition and were not used for qPCR analysis. We
evaluated expression of the following genes: acetyl-CoA carbox-
ylase isoforms (acca: marker of FA synthesis; accb: marker of FA
oxidation); fatty acid synthase (fasn: marker of FA synthesis);
glycerol-3-phosphate acyltransferase (mitochondrial) (gpam: marker
of glycero-lipid synthesis); hydroxyl-3-methyl-glutaryl-CoA reduc-
tase (hmgcr: marker of cholesterol synthesis); LDL receptor (ldlr:
marker of LDL metabolism); SREBP isoforms (srebpf1/2: evaluate
role of SREBPs); and glutamine fructose-6-phosphate amidotrans-
ferase (gfat1: HBP marker). For all qPCR reactions, 2 mL of diluted
cDNA (range ,2–5 ng of cDNA) was used in technical triplicate
reactions using LightCyclerH 480 Probes Master mix (Roche,
Indianapolis IN) for 59 exonuclease chemistry with primers and
probes per manufacturer specifications (Primers [forward/re-
verse]: actb – cccgcgagtacaaccttct/cgtcatccatggcgaact; hprt1 –
gaccggttctgtcatgtcg/acctggttcatcatcactaatcac; pgk1 – ccagataacgaa-
taaccaaagga/gacttggctccattgtcca; gapdh – agctggtcatcaatgggaaa/
atttgatgttagcgggatcg; g6pdh – ttatcatcatgggtgcatcg/aaggtgtcttcggg-
tagaagg; gusb – ctctggtggccttacctgat/cagactcaggtgttgtcatcg; tbp –
cccaccagcagttcagtagc/ cccaccagcagttcagtagc; RNA – tgcaagc-
caattcccgaag/ ccattgtagtgaacagtaggac and Probes: 18S –
Hs99999907_s1; acaca – Rn00573474_m1; acacb –
Rn00588290_m1; fasn – Rn00569117_m1; gfpt1 –
Rn01765492_m1; gpam – Rn00568620_m1, hmgcr –
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Rn00565598_m1, ldlr – Rn00598442_m1, srebf1 –
Rn01495769_m1; srebf2 – Rn01502638_m1)(Life Technologies,
Grand Island NY; Roche, Indianapolis IN; Thermo Scientific,
Waltham MA).
Reactions were run on the LightCycler H 480 qPCR instrument
(Roche, Indianapolis IN). Relative quantification was calculated
using the DCq method corrected for amplicon efficiencies (range =
1.9–2.1). Reference gene fitness was determined by measuring a
panel of genes: 18s, Actb, G6pdh, Gapdh, Hprt1, Pgk1, and Tbp.
The most stable genes across the three conditions for each tissue
was determined using the NormFinder algorithm [33,34];
subsequently, the GeNorm algorithm [33,34] was used to
calculate the number of reference genes needed to maximize
stability. For adipose tissue and liver tissue, three reference
genes were utilized (G6pdh, Hprt, Pgk1- variation (V) = 0.3; and
18s, Tbp, Gapdh – V = 0.1, respectively) and for heart tissue,
four reference genes were used (18s, G6pdh, Hprt1, Tbp –
V = 0.4).
Relative target gene expression levels were determined using the
DCq method followed by reference gene normalization as
described [34].
Proteasome activity measurements. Chymotrypsin-like,
trypsin-like, and caspase-like activities of the proteasome were
assayed using fluorogenic peptides (Sigma-Aldrich, St Louis,
MO): Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (LLVY-
MCA at 25 mM), N-t-Boc-Leu-Ser-Thr-Arg-7-amido-4-methyl-
coumarin (LSTR-MCA at 40 mM) and N-Cbz-Leu-Leu-Glu-b-
naphthylamide (LLE-NA at 150 mM), respectively, as described
before by us [35].
Western blotting analysis. Total protein was extracted
from tissue samples as described [36], while nuclear protein
extraction was performed using the high-salt extraction method
[37]. Protein concentrations for both total and nuclear lysates were
determined by the Lowry method and Western blotting performed
for: SREBP-1 for cytosolic (cSREBP-1) and nuclear (nSREBP-1)
proteins, calmodulin, calcineurin, phosphorylated calcium/cal-
modulin-dependent kinase II (pCaMKII), nuclear factor of
activated T-cells 3 (NFAT3), phosphorylated phospholamban
(pPLB), peroxisome proliferator-activated receptor gamma coacti-
vator-1-alpha (PGC-1a), mitochondrial transcription factor A
(mtTFA), nuclear respiratory factor 1 (NRF-1), connexin 43 and
ubiquitin. Protein detection was performed using standard
methods [36] and expression determined by the adjusted
percentage volume (intensity units of band x mm2) after
background subtraction and normalized to b–actin or Ponceau
stain to correct for variations in loading. Primary antibodies
(rabbit or mouse) were purchased from Santa Cruz Biotechnol-
ogies (Santa Cruz Biotechnologies, Santa Cruz CA) or Cell
Signaling (Cell Signaling, Danvers MA) to be used at 1:1000
dilution with corresponding secondary antibody (anti-rabbit or
anti-mouse HRP-linked antibodies at 1:4000 dilution).
Evaluation of myocardial oxidative stress. Superoxide
dismutase (SOD) (Enzo Life Sciences, Farmingdale NY) activity
was measured in mitochondrial preparations (prepared according
to Boudina et al. [38]) following the manufacturer’s instructions.
The catalase activity assay is based on the properties of catalase
enzyme to reduce hydrogen peroxide (H2O2) into oxygen (O2) and
water (H2O) [39]. Assays were carried on about 80 mg of protein
lysate in 25 mM Tris–HCl (pH 7.5). Blanks were measured at
240 nm just before adding 80 mL of H2O2 (10 mM final) to start
the reaction. Catalase activity was determined by measuring the
absorbance decrease of H2O2 at 240 nm. The decomposition of
hydrogen peroxide is a first order reaction type following H2O2
concentration and the rate constant K for the overall reaction is
given by:
K~
2:3
Dt
 log (DOzero
DOt
)
Each measurement was considered with 4 replicates and data are
expressed as catalytic unit (U) per mg of total protein. Protein
carbonylation was performed on heart tissues as described before
[40].
Determination of non-oxidative pathway
activation. Briefly, collected heart tissues were homogenized
with modified ice-cold RIPA buffer, the supernatant centrifuged
twice at 13, 000 g for 10 min at 4uC then stored at 280uC until
further use. We employed Western blotting analysis to determine
total O-GlcNAc expression as a marker for myocardial HBP
activation, and methylglyoxal concentrations to assess AGE
pathway activation (OxiSelectTM MG ELISA Kit; Cell Biolabs,
San Diego CA). Methylglyoxal derivatives are formed from the
non-enzymatic reaction of reducing carbohydrates such as
glucose and carbonyl compounds (glyceraldehyde) in the Maillard
reaction – products of this reaction are called AGEs. MG levels
were calculated from the standard curve and are expressed as
nmol per mg protein. The PKC assay was carried out using an
ELISA-based method as detailed in the kit’s instruction manual
(Enzo Life Sciences, Farmingdale NY). PKC activity was
determined from the standard curve and expressed as ng/min/
mL.
D-sorbitol, an intermediate of the polyol pathway was measured
as an index of pathway activation. D-sorbitol levels were measured
as detailed in the instructions of a commercially obtained kit
(BioVision K 631-100, Mountain View CA). We calculated the
sorbitol concentration (C) of samples by using the sample amount
(nmol) from the standard curve (Sa), sample volume (mL) used (Sv)
and the dilution factor (D); C = Sa/Sv*D. We used a modified
protocol (EC 2.2.1.1) from Sigma Aldrich (St. Louis MO) to
determine transketolase activity as a marker of the non-oxidative
branch of the pentose phosphate pathway (PPP). Briefly, xylulose
5-phosphate and ribulose 5-phosphate are converted by transke-
tolase in the presence of magnesium ions and thiamine pyrophos-
phate to glyceraldehyde 3-phosphate and sedoheptulose 7-
phosphate. G 3-P is then further converted by triosephosphate
isomerase to dihydroxyacetone phosphate, and with the addition
of b-NADH and a-glycerophosphate dehydrogenase to produce a-
glycerol phosphate and b-NAD to be measured spectrophotomet-
rically at 340 nm. This protocol was adapted from de la Haba et
al.(1955) [41].
Statistical analyses. Data are presented as mean 6 SEM,
and values considered significant when p,0.05. Statistical analysis
was performed by one-way ANOVA, with the exception of heart
function (two-way ANOVA). The Bonferroni post-hoc test com-
paring all groups to each other were used to determine differences
(GraphPad Prism v5, San Diego CA).
Results
Fasting serum levels for FFA, TG, total cholesterol, insulin and
glucose were not significantly altered with chronic PI treatment
(Fig. 1), with HOMA-IR also not showing any differences (data
not shown, p.0.05). However, PI treatment increased serum
LDL-cholesterol levels to 0.43360.021 vs. 0.21660.005 mM
(sham) (p,0.05) and vs. 0.21660.005 mM (vehicle) (p,0.05).
Furthermore, triglyceride content was significantly elevated in
heart (Fig. 1G) and liver tissues (data not shown), while PI-treated
hearts also exhibited higher HDL-cholesterol levels (p,0.01 vs.
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sham and vehicle) (Fig. 1H). No significant elevations were
found for cardiac total cholesterol and VLDL-cholesterol content
(p.0.05) (Fig. 1 E, F). In addition, total food consumed in
PI-treated animals was significantly higher than the control
groups; i.e. 894617.8 g vs. 707614.3 g (sham) (p,0.05) and vs.
717613.1 g (vehicle) (p,0.05).
Figure 1. Serum and tissue lipid characterization (n=8). A) serum FFA; B) serum LDL-cholesterol; C) serum TG; D) serum total cholesterol; E)
cardiac total cholesterol; F) cardiac LDL-cholesterol; G) cardiac TG; and H) cardiac HDL-cholesterol. *p,0.05, **p,0.01 vs. sham;#p,0.05,##p,0.01
vs. vehicle. Data presented as mean 6 SEM and one-way ANOVA with Bonferroni post-hoc test performed for statistics. FFA – free fatty acids, HDL –
high density lipoprotein, LDL – low density lipoprotein, PI – protease inhibitor, TG – triglyceride.
doi:10.1371/journal.pone.0073347.g001
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Histological analysis (H & E staining) did not reveal major
ultrastructural abnormalities for all tissues examined (Fig. 2A)
while no fibrosis was detected (data not shown). To determine
mechanisms responsible for early metabolic changes, we evalu-
ated lipid and cholesterogenic genes in heart and liver tissues.
Here PI treatment enhanced cardiac gpam expression (p,0.001
vs. sham), although this was not significant vs. vehicle-treated rats
(Fig. 2B). However, hepatic accb and hmgcr expression were
significantly upregulated in the PI group (p,0.05 vs. vehicle)
(Fig. 2C). Since our gene data indicate PI-mediated transcrip-
tional effects, we next assessed the expression of the transcrip-
tional modulator SREBP-1. However, we found no significant
alterations with PI treatment for nuclear (Fig. 2D) and cytosolic
SREBP1 (data not shown).
Further analyses of heart function at baseline revealed
significantly decreased contractile force with PI treatment. Here
both maximal and minimal contractile forces were altered with 8
weeks of PI therapy (Table 1) when compared to both sham and
vehicle-treated groups. No significant differences were found
between the respective control groups.
We next evaluated the effects of PI treatment on the cardiac
UPS system and our data demonstrate significantly lowered
chymotrypsin-like and caspase-like, but not trypsin-like proteaso-
mal activities (Fig. 3A). In parallel, global ubiquitination of total
proteins significantly increased with PI administration (Fig. 3B).
Since our earlier work pointed towards an alteration in SERCA-2a
levels [17], we attempted to gain additional insight regarding PI-
mediated contractile dysfunction, markers regulating this ion
channel as well as a marker for electrical conductance. Here
myocardial expression of the gap junction protein connexin 43
(marker for electrical conductance) and pPLB (SERCA-2a
regulator) increased with PI treatment (Fig. 3C, D).
Figure 2. Gene and histologic characterization (n=8). A) H & E staining for various tissues following PI treatment; B) Heart; and C) liver gene
regulation; and D) nuclear SREBP protein expression. **p,0.01, ***p,0.001 vs. sham; #p,0.05, ##p,0.01 vs. vehicle. Data presented as mean 6
SEM and one-way ANOVA with Bonferroni post-hoc test performed for statistics. H & E – hematoxylin and eosin, LDL – low density lipoprotein, PI –
protease inhibitor, SREBP – sterol regulatory element binding protein, gene abbreviations – refer Methods section.
doi:10.1371/journal.pone.0073347.g002
Table 1. Effect of PIs on ex vivo heart function parameters at
baseline (n = 8).
Sham Vehicle PI
+dP/dt (mmHg/
sec)
1411.06126.9 1068.8670.9 633.1657.7 ***, #
2dP/dt (mmHg/
sec)
2966.8671.9 2782.16118.2 2338.4631.0 ***, ##
Heart rate (bpm) 274.1610.6 283.569.2 197.4636.0
Abbreviations: PI – protease inhibitor.
***p,0.001 vs. sham; #p,0.05 and ##p,0.01 vs. vehicle.
Data presented as mean 6 SEM and two-way ANOVA with Bonferroni post-hoc
test performed for statistics. No significant differences were found between the
sham and vehicle groups, and statistical differences for PI are indicated with * or#
symbols.
doi:10.1371/journal.pone.0073347.t001
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We next assessed calcium and mitochondrial energetic
signaling markers and found that PIs significantly downregulated
the expression of the calcium-binding protein calmodulin
(Fig. 4A), while calcineurin was upregulated (Fig. 4B). However,
pCaMKII levels remained unchanged while nuclear NFAT3
expression increased versus controls (p,0.05 vs. sham and
vehicle) (Fig. 4C, D). Here expression of PGC-1a was
significantly upregulated in PI-treated heart tissue (Fig. 5A)
while no changes were found for mitochondrial biogenesis
markers (NRF-1, mtTFA) (Fig. 5B, C).
Myocardial SOD activity within mitochondria was markedly
upregulated (Fig. 6A, B) in PI-treated hearts. However, cardiac
catalase activity and protein carbonylation did not differ for any
of the experimental groups (Fig. 6C, D). The non-oxidative
glucose pathways did not display any significant changes, except
that PI treatment attenuated the AGE pathway, i.e. 6.2560.52
vs. 14.8762.05 nmol/mg protein (sham) (p,0.01) and vs.
13.1662.23 nmol/mg protein (vehicle) (p,0.05) (Fig. 7).
Discussion
Although HAART markedly improves the quality of life and
prognosis of HIV-infected individuals, it also elicits cardio-
metabolic side effects in the long-term. Since molecular mecha-
nisms underlying this process are poorly understood, we evaluated
early cardio-metabolic changes in a rat model of PI treatment.
The main findings of this study are: 1) PI-treated rats exhibited
lipid abnormalities; and 2) Rats exposed to PIs display altered
myocardial ubiquitin proteasome and calcium-handling pathways
together with decreased contractile function.
PI-treated rats exhibited lipid abnormalities. Previous
studies demonstrated that a significant proportion of HAART
patients develops impaired glucose tolerance, IR and type 2
diabetes [11,12]. Here our data revealed that PI-treated rats
displayed elevated serum LDL-cholesterol and cardiac/hepatic
tissue triglyceride levels, identifying perturbed lipid metabolism
as a relatively early occurrence. Although not focusing on initial
PI-mediated changes, previous work also reported that lipid
derangements are one of the commonest side-effects triggered by
Lopinavir/Ritonavir usage [42]. Moreover, clinical studies
indicate that altered fat partitioning (i.e. lipodystrophy) is
common with PI treatment [7,43,44] compared to overt
increases in weight gain, and that this occurs within the first
year of therapy. Our data indicate that the onset of IR could
follow at a later stage in the progression of cardio-metabolic
dysfunction following PI treatment. In support, the HOMA-IR
assessment and several non-oxidative pathways of glucose
metabolism (HBP, PKC, polyol pathway), that are usually
strongly linked to IR and type 2 diabetes, were not activated
in our model. However, the AGE pathway was unexpectedly
downregulated and further studies are required to elucidate
whether this is a direct effect or if it occurs as a result of other
changes triggered by PI treatment.
How exactly does PI treatment induce the changes in lipid
metabolism here observed? The mechanisms underlying higher
food consumption with PI exposure are unclear, but well-known
regulators of dietary intake (e.g. leptin, neuropeptide Y, ghrelin)
may be implicated [45] and therefore form part of our ongoing
investigations. PI treatment induced gene expression of accb and
hmgcr in the liver that would be expected to enhance fatty acid
oxidation and cholesterol synthesis, respectively. There were also
early signs of elevated cardiac gpam expression (although not
statistically significant versus all matched controls), while it was
robustly upregulated in adipose tissue (data not shown). The
Figure 3. Proteasome and protein expression of contractile regulators following PI treatment (n=8). A) LLVY (chymotrypsin-like
activity), LSTR (trypsin-like activity), and LLE (caspase-like activity) of the proteasome; B) Total protein ubiquitination; C) Connexin 43; and D)
Phosphorylated PLB. *p,0.05, **p,0.01, ***p,0.001 vs. sham; #p,0.05 vs. vehicle. Data presented as mean 6 SEM and one-way ANOVA with
Bonferroni post-hoc test performed for statistics. pPLB – phosphorylated phospholamban, PI – protease inhibitor.
doi:10.1371/journal.pone.0073347.g003
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gene expression results therefore indicate that the higher serum
LDL-cholesterol levels may result from greater adipose triglyceride
synthesis and subsequent export to the liver and heart. Here
increased hepatic hmgcr expression may enhance VLDL produc-
tion and with a corresponding elevation in the availability of
circulating LDL-cholesterol.
Figure 4. Calcium pathway protein expression in response to chronic PI therapy (n=6–8). A) Calmodulin; B) Calcineurin; C) pCaMKII; and
D) NFAT3. *p,0.05, **p,0.01 vs. sham; #p,0.05, ##p,0.01 vs. vehicle, ###p,0.001 vs. vehicle. Data presented as mean 6 SEM and one-way
ANOVA with Bonferroni post-hoc test performed for statistics. NFAT3 – nuclear factor of activated T-cells 3, pCaMKII – phosphorylated CaMKII, PI –
protease inhibitor.
doi:10.1371/journal.pone.0073347.g004
Figure 5. Myocardial peptide levels of transcriptional regulators of cardiac hypertrophy and mitochondrial biogenesis with 8
weeks PI therapy (n=6–8). A) PGC-1a; B) NRF-1; and C) mtTFA. ***p,0.001 vs. sham; ###p,0.001 vs. vehicle. Data presented as mean 6 SEM
and one-way ANOVA with Bonferroni post-hoc test performed for statistics. NRF-1 nuclear respiratory factor 1, mtTFA – mitochondrial transcription
factor A, PGC-1a – peroxisome proliferator-activated receptor gamma coactivator-1-alpha, PI – protease inhibitor.
doi:10.1371/journal.pone.0073347.g005
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Figure 6. Myocardial oxidative stress profile (n =8). A) Mitochondrial SOD activity; B) Protein carbonylation; and C) Myocardial catalase activity.
***p,0.001 vs. sham; ###p,0.001 vs. vehicle. Data presented as mean 6 SEM and one-way ANOVA with Bonferroni post-hoc test performed for
statistics. PI – protease inhibitor, SOD – superoxide dismutase.
doi:10.1371/journal.pone.0073347.g006
Figure 7. Profile of cardiac non-oxidative metabolic pathways (n=8). A) AGE; B) PKC; C) Polyol pathway (D-sorbitol); D) HBP (O-
GlcNAcylation); and E) Pentose phosphate pathway (transketolase). *p,0.05 vs. sham;#p,0.05 vs. vehicle. Data presented as mean6 SEM and one-
way ANOVA with Bonferroni post-hoc test performed for statistics. AGE – advanced glycation end-products, HBP – hexosamine biosynthetic pathway, PI
– protease inhibitor, PKC – protein kinase C.
doi:10.1371/journal.pone.0073347.g007
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Since PIs may also have direct transcriptional effects that trigger
gene expression, we also assessed whether SREBPs – well-known
transcriptional regulators of several lipid and cholesterol synthesis
genes [23] – are implicated in the observed gene induction. We
found no significant differences when analyzing SREBP expression
(gene and protein levels) in liver and heart tissues, and suggest that
other transcriptional modulators that regulate lipid and cholesterol
genes may be involved. An alternate explanation may relate to the
fact that Ritonavir is a reversible and competitive inhibitor of
specific 20S proteasome subunits [25]. Since the UPS also plays a
key role to regulate SREBP-1 binding to target gene promoters
(mediating its degradation) [27,28], lower UPS activity may lead to
more SREBP-1 remaining bound to gene promoter(s). This in turn
could result in greater induction of target genes, even though total
SREBP expression levels were unaltered. These possibilities are
currently being pursued in our laboratory.
Together our study shows that early changes induced by PI
treatment resemble the metabolic syndrome, a combination of risk
factors that predispose to the future onset of IR, type 2 diabetes
and CVD. Moreover, the higher serum LDL-cholesterol levels
mirror a pre-atherogenic state that may eventually trigger the
onset of various cardiac complications, e.g. acute myocardial
infarction.
Rats exposed to PIs display altered myocardial ubiquitin
proteasome and calcium-handling pathways together
with decreased contractile function
What are the underlying mechanisms whereby PI administra-
tion impairs contractile function? Our results show no significant
remodeling of hearts exposed to PIs, i.e. lack of ultrastructural
changes, fibrosis and cardiac hypertrophic response. We also
evaluated markers for myocardial oxidative stress since others
found a link between PI exposure and elevated ROS production
[18–20], but found no evidence of damaging effects of myocardial
oxidative stress at baseline (no changes in degree of protein
carbonylation). However, PI-treated hearts exhibited augmented
myocardial SOD activity suggesting that increased oxidative stress
is blunted by intracellular defense systems. Thus, these data
indicate that harmful effects of previously reported PI-induced
ROS occur at a later stage during the HAART regimen. In
agreement, there was no ROS-mediated induction of several non-
oxidative glucose metabolic pathways in PI-treated rats. This
contrasts our recent work where greater myocardial oxidative
stress, HBP activation and apoptosis contributed to contractile
dysfunction [35].
The heart functional data are consistent with our earlier work
[17] and reveal attenuated contractile function without significant
alterations to heart rate. Here the 6dP/dt findings implicate the
myocardial calcium handling pathway, as diastolic calcium is a key
determinant of contractile function and calcium signaling [46].
Since PI treatment decreased and increased myocardial UPS
activity and ubiquitination, respectively, this may lead to an
accumulation of contractile protein aggregates and impaired
cardiac contractility and signaling pathways. For example, protein
turnover of connexin 43, PLB and SERCA-2a are all regulated by
the UPS [47–51] and may explain the higher expression levels
found here and before by us [17]. Others have established that
altered connexin 43 expression can precede arrhythmias, ventric-
ular fibrillation and incorrect signal propagation in the long-term
[52–57]. Therefore we tentatively suggest that elevated connexin
43 expression in our model may results in detrimental effects on
contractile function in the future, especially within the context of
HIV-AIDS.
We previously identified lower myocardial calcium levels and
higher SERCA-2a protein expression with PI treatment [17],
and now report attenuated and elevated calmodulin and pPLB
expression levels, respectively. In parallel, we found increased
myocardial calcineurin and NFAT3 expression levels. Of note,
others found that cardiac-specific calcineurin overexpression
resulted in enhanced pPLB and SERCA-2a expression and
diminished phosphorylation and redistribution of connexin 43
[58]. This was associated with depressed contractility and cardiac
hypertrophy. Here the authors proposed that connexin 43 may
be a downstream target of calcineurin and that attenuated
connexin 43 levels may be linked to perturbed gap junction
assembly and arrhythmogenesis [58]. We propose that a similar
scenario may exist in our model and that greater calcineurin
activation is linked to elevated connexin 43 expression that may
compromise gap junction function. Increased SERCA-2a,
connexin 43 and pPLB expression may occur as a result of
lower myocardial UPS and have also been implicated as
downstream transcriptional targets of calcineurin [58]. Thus,
elevated connexin 43 and pPLB expression may represent an
adaptive response by PI-treated hearts to improve calcium
handling, which may improve cardiac function. Higher calci-
neurin activation also leads to increased dephosphorylation and
translocation of NFAT3 to the nucleus for activation of
downstream targets, e.g. PGC-1a and pro-hypertrophic genes
[59,60]. However, since the calcineurin-NFAT3 pathway did not
result in cardiac hypertrophy in our model, we are of the opinion
that longer-term activation may eventually result in a hypertro-
phic response. These findings, however, represent a model of
altered cardiac physiology and suggest a potential association
with PI-induced molecular alterations to key junction and ionic
proteins that may precede the onset of contractile dysfunction.
Moreover, the metabolic side-effects elicited by PI treatment in
our model – although at a relatively early stage – may also affect
heart function as a downstream target. Thus we do not imply
that the protein expression alterations are directly associated with
the altered contractility found in our model. Data linking these
phenomena are scarce and therefore makes definitive conclusions
difficult. Together these findings indicate that perturbed calcium
handling may contribute to the PI-mediated contractile dysfunc-
tion found in our experimental model in the longer term.
However, further studies are required to confirm whether this is
indeed the case.
Since myocardial PGC-1a was upregulated, this implies that PIs
exert initial effects at the mitochondrial level. PGC-1a is a well-
described transcriptional regulator of mitochondrial biogenesis
[61,62] and we propose that higher expression levels may
represent an early compensatory response to energetic stress. In
agreement with this notion, NRF-1 and mtTFA expression
remained unaltered while we previously identified no changes
for myocardial ATP levels and AMPKa expression following 8
weeks of PI administration [17]. It is likely that reduced UPS
activity in PI-treated hearts may contribute to the increased PGC-
1a levels here observed. In support, others established that lower
UPS-mediated protein turnover in fibroblasts resulted in PGC-1a
stabilization and mitochondrial biogenesis [63], while it can also
be rapidly degraded in the nucleus [64]. The reason(s) as to why
NRF-1 and mtTFA were not upregulated in response to PGC-1a
remains unclear but could be a unique phenomenon within this
animal model. Therefore we cautiously interpret our findings and
conclude a potential association between proteasomal inhibition
via PIs and activation of the PGC-1a pathway.
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Study limitations
The data here generated do not allow us to make a direct causal
link between metabolic/molecular alterations and decreased heart
function with PI treatment. We propose that additional studies
that investigate more markers of electrical conductance, ion
homeostasis and mitochondrial biogenesis would be useful to help
answer these questions. Further, transgenic mouse studies to
generate gene knockout/knockdown of molecular targets here
identified, together with PI exposure should further advance our
understanding of PI-mediated cardio-metabolic complications.
In conclusion, our study demonstrates that early changes
triggered by PI treatment include increased serum LDL-choles-
terol and myocardial triglyceride levels, together with decreased
cardiac function. Furthermore, PI exposure inhibits the myocar-
dial UPS and leads to elevated calcineurin and connexin 43
expression that may contribute to cardiac contractile dysfunction
in the long-term. Our findings also highlights potential molecular
targets that may have detrimental metabolic and contractile
effects. Thus our study alerts to the association between PI
treatment and cardio-metabolic side effects and we propose that
further clinical studies are needed to evaluate these pathways in
HIV+ patients on chronic HAART.
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